Last updated 11.02.2019

Oncoinvent
Company
Summary

Reports

Quarterly reports
-

Annual reports
-

Other reports
-

Quarterly report Q3 2019 (Norwegian)

Quarterly report Q3 2019 (Norwegian)

Quarterly report Q3 2019 (English)

Quarterly report Q3 2019 (English)

Quarterly report Q2 2019 (Norwegian)

Quarterly report Q2 2019 (Norwegian)

Quarterly report Q2 2019 (English)

Quarterly report Q2 2019 (English)

Quarterly report Q1 2019 (Norwegian)

Quarterly report Q1 2019 (Norwegian)

Quarterly report Q1 2019 (English)

Quarterly report Q1 2019 (English)

Presentations

Date published
-

  • This is a press release dertim Porerati ius volor simi
  • Tem sapere volo
  • This is a press release dertim Porerati ius volor simi
  • Tem sapere volo

Presentations by year

Quarterly Presentation Q3-2019

Quarterly Presentation Q3-2019

Quarterly Presentation Q2 2019

Quarterly Presentation Q2 2019

Norwegian Biotech Oncology Seminar 2019 (ABG Sundal Collier)

Norwegian Biotech Oncology Seminar 2019 (ABG Sundal Collier)

Jan Alan Alfheim

Chief Executive Officer

alfheim@oncoinvent.com

+47 464 40 045

Jan A. Alfheim is a business executive with over thirty years’ experience bringing product ideas and technology to the chemical and pharmaceutical markets, from product concept inception through discovery and development phases to final marketing campaign and launch.

With experience in research, project management, business development & partnering, company start-ups, and product launches, Alfheim comes from Nordic Nanovector ASA where he was Chief Executive Officer from 2011 until 2014 and Chief Operating Officer from 2014 to 2016. Prior to working at Nordic Nanovector, he has held various senior roles including Chief Business Officer at Clavis Pharma, President of StemPath Inc, Director of Business Development at Neurochem Inc and Project Director at Nycomed Imaging. Mr. Alfheim holds a MSc from Concordia University and a MBA from McGill University.